Category: Health

  • Nit Happens, A New Clinically Proven Non-Toxic Lice Treatment Now Available at Walgreens

     

    nithappensproduct

    The gentle and highly effective lice treatment is available at 6,000 Walgreens locations in the United States

    DALLAS, TX (Mar16)- Cartwheel, a healthcare brand developed by moms for moms, is today announcing the availability of its inaugural consumer product, Nit Happens, at 6,000 Walgreens locations in the United States. The over-the-counter lice treatment uses only non-toxic, naturally-derived ingredients to eliminate lice and nits, avoiding the pesticides and synthetic ingredients found in many traditional treatments. 

    “We’re thrilled to launch Nit Happens in Walgreens stores nationwide, making it easier for families across the country to access a safer lice treatment that takes some of the stress out of what can be a chaotic experience,” said Joanna Shu, CEO of Cartwheel. “As a mom of three kids who have all had lice at some point, I experienced firsthand how difficult lice are to treat and how many products rely on harsh pharmaceutical ingredients. Parents shouldn’t have to choose between safety and effectiveness. We’re giving them both, plus a splash of humor to lighten the load.”

    Unlike harsh chemical formulas, Nit Happens works through physical disruption and dehydration. Its gel combines coconut oil, mild cosmetic abrasives, and limonene derived from orange peels to kill lice and nits when combined with gentle brushing. 

    The results are clinically proven. A clinical study reported a 95.8% efficacy rate when the label instructions were followed. With treatment-resistant lice becoming more prevalent, these results point to a strong alternative for families who need reliable outcomes without harsh chemical exposure. 

    An estimated 6 to 12 million children in the U.S. get head lice each year, and misdiagnosis is extremely common. Parents often confuse dandruff, sand, debris, and scalp conditions with lice, leading to unnecessary stress and unnecessary treatment. Cartwheel is positioning Nit Happens as part of a larger effort to improve education and awareness around lice. The company is currently developing a new smartphone application to help parents better determine if their child actually has lice using guided check steps.

    The Nit Happens OTC Lice Treatment Kit includes: 

    • 4 oz treatment gel (two full applications)

    • 1 oz post-treatment shampoo

    • Metal lice comb

    • Applicator brush

    • Gloves

    Nit Happens will also soon be available for purchase on the TikTok Shop and Amazon.

     

  • What’s at Stake Beyond the Smile

    Studies have shown associations between oral conditions, particularly periodontal disease, and systemic ailments, some of them life-threatening and all affecting quality of life.

    What does the condition of your teeth, gums, and jaws have to do with your heart, brain, and guts? More than you might realize.

    The public perception of the mouth as separate from the body—a sort of self-sustaining city within a larger country—has held sway for decades. Yet “more and more research is showing the impact of oral disease on general health, and it is much greater than it was once thought to be,” says Athanasios Zavras, who leads the Department of Public Health and Community Service at Tufts University School of Dental Medicine. 

    Significant data exist on the association between various oral conditions, particularly periodontal disease, and systemic ailments, some of them life-threatening and all affecting quality of life. And the relationship is reciprocal. Just ask anyone with diabetes whose disease was first flagged through their swollen, bleeding gums.

    “I think we are in a good position to address these issues, and prevent and treat oral disease, which will eventually benefit all of human health,” says Jake Jinkun Chen, professor of basic and clinical translations sciences at the School of Dental Medicine. In his lab, Chen and his team are searching not just to find common underlying mechanisms that connect oral and systemic diseases, but to find strategies that could prevent or treat them, including Type 2 diabetes, osteoporosis, Alzheimer’s, and autoimmune diseases like Sjorgen’s and rheumatoid arthritis.

    In the meantime, what can we do to protect our oral, and thus overall, health? In a word, prevention. “Pay very meticulous attention to oral health,” says Zavras, the Delta Dental of Massachusetts Professor in Public Health and Community Service. “It should require some minutes of someone’s time twice a day.” 

    And that attention should encompass the whole mouth. For too long, Zavras says, the focus has been solely on our pearly whites. “It’s the teeth and gums,” he stresses.

    The Vital but Messy Microbiome

    Why does what happens in the mouth not stay in the mouth? The answer is the oral microbiome, which is basically “all the germs we have in our mouths and how they travel to distant sites in the body,” says Zavras.

    The mouth is the point of entry for numerous bacteria and viruses, and the immune cells that live there can become the first to fight off those pathogens. For example, Hend Alqaderi, an assistant professor in the Department of Public Health and Community Service, has found people who developed severe cases of COVID-19 had considerably different oral bacteria than those with milder symptoms. 

    Infections that begin in the mouth can also spread through the bloodstream to other parts of the body. Zavras refers to the dramatic case of a Maryland preteen who died in 2007 after he was unable to get timely treatment for a dental abscess and the infection eventually attacked his brain. Similarly, pathogens that are inhaled through the mouth can contribute to respiratory conditions like pneumonia. 

    Why aren’t these connections better known? Talking about microbes in the mouth can be off-putting for the public, says Yau-Hua Yu, an associate professor of periodontology who has examined the association between self-reported poor oral health and negative long-term systemic health outcomes.

    When oral care is presented as being all about smiles, that’s very appealing, she says. “But when we start to think about other things in the oral cavity”—say, saliva, bacteria, and mucous membranes—“that can be a little messy,” and people become less receptive to oral health messages. 

    Yu sees hope in the recent popular emphasis on gut health. “The microbiome has become very trendy,” she says. “But the microbiome starts at the oral cavity.” 

    A Drop in the Bucket

    Approximately 47% of people over age 30 in the U.S. have some form of periodontal disease: essentially, inflammation and infection of the tissues that support the teeth. It can range from mild recession to gingivitis to severe periodontitis, and eventually endanger the teeth and jawbone.

    “Numerous studies show periodontal disease may increase risk of cardiovascular disease, heart attack, stroke, and hardening of the arteries,” says Natalie Jeong, professor and chair of the Department of Periodontology.

    Jeong stresses that a direct causal relationship has not been definitively established between these cardiovascular conditions and periodontal disease. “But both share common risk factors: smoking, diabetes, age, even lifestyle factors like poor diet, lack of exercise, and obesity,” she says.

    There is also a strong correlation between periodontal disease and diabetes—both Type 1 and Type 2—and it goes in both directions, Jeong says. “If blood glucose is well-controlled, the state of periodontal disease improves; when periodontal disease is treated, glycemic control tends to improve.” Oftentimes, she says, when a newly diagnosed periodontal patient, particularly a younger person, does not respond to initial treatment, that’s a sign that undiagnosed diabetes is also likely in the mix, Jeong says. 

    Oral disease is just one of many conditions that promote systemic inflammation, says Nadeem Karimbux, dean of the School of Dental Medicine and a professor of periodontology. But that doesn’t mean it should be minimized, either.

    He uses the metaphor of several taps—various risk factors—dripping into a bucket, the collected stresses on the body’s health. Eventually, the bucket spills over into heart disease or other ailments, “The drip from the oral health condition may just be one more contributing factor that pushes you over the edge,” Karimbux says.

  • 9 Essential Ways to Evaluate a Reliable Health Insurer in 2026

    9 Essential Ways to Evaluate a Reliable Health Insurer in 2026

    Pic Credit: Pexel

    Selecting the right health insurer is one of the most important decisions you can make for your family’s well-being. With healthcare costs rising and insurance options expanding, it’s crucial to choose a provider that offers reliable coverage, excellent support, and smooth access to medical care. In 2026, several real-world factors can help you assess which health insurer is truly trustworthy.

    1. Check the Network of Hospitals

    A good health insurer should have an extensive network of hospitals in your city and across the country. Verify whether your preferred hospitals, both for emergencies and routine treatments, are included. A wide network ensures you have access to quality care without hassle or delays.

    2. Cashless Facility

    Cashless hospitalization is one of the most sought-after benefits. Check if the insurer provides cashless treatment options at network hospitals. This feature allows you to receive care without upfront payments, easing financial stress during medical emergencies.

    3. Customer Support

    Reliable insurers offer responsive customer support to assist with claims, policy details, and emergency guidance. Look for companies that provide multiple communication channels, including phone, chat, and mobile apps, so help is available whenever needed.

    4. Claim Settlement Record

    Research the insurer’s claim settlement ratio and customer reviews. High settlement ratios indicate a smooth and transparent claims process, while low ratios may signal delays or frequent disputes.

    5. Coverage and Inclusions

    Compare policies for coverage details, including hospitalization, pre-existing conditions, day-care procedures, and critical illness benefits. A trustworthy insurer clearly outlines what is included and excludes hidden clauses.

    6. Flexibility and Portability

    Choose a health insurer that allows policy portability, enabling you to switch plans without losing benefits. Flexible policies that accommodate changing health needs over time provide long-term security.

    7. Premium Transparency

    Ensure that premiums are transparent and aligned with the coverage offered. Avoid insurers who offer low initial premiums but have high deductibles or hidden charges.

    8. Reviews and Recommendations

    Check online reviews and ask for recommendations from family, friends, or healthcare providers. Real-world experiences often reveal strengths and weaknesses of insurers that official brochures may not highlight.

    9. Value-Added Services

    Many insurers now offer additional services such as teleconsultations, health check-ups, wellness programs, and mental health support. These value-added services can improve your overall healthcare experience and support preventive care.

    Top Health Insurers to Consider in 2026

    Some trusted health insurers in India in 2026 include HDFC ERGO Health Insurance, ICICI Lombard General Insurance, Max Bupa Health Insurance, Star Health and Allied Insurance, and Aditya Birla Health Insurance. These companies are known for extensive hospital networks, reliable cashless facilities, and high customer satisfaction.

    Final Thoughts

    Choosing a health insurer is not just about the cheapest premium—it’s about trust, reliability, and seamless support when you need it most. By evaluating hospital networks, cashless facilities, claim records, coverage, and real-world customer experiences, you can select a health insurer that gives you peace of mind and financial security in 2026 and beyond.

  • Growing Implants Bring New Hope to Children with Bone Cancer

    Growing Implants Bring New Hope to Children with Bone Cancer

    Pic Credit: Pexel

    A new medical innovation called the “growing implant” is transforming the treatment of bone cancer in children. The technique allows surgeons to remove cancer-affected bone while preserving the limb and enabling it to grow normally, improving long-term mobility and quality of life.

    Bone cancers such as osteosarcoma and Ewing sarcoma often affect children and adolescents. Traditional treatments sometimes required amputating the limb or resulted in permanent differences in leg length, creating long-term physical and emotional challenges. Growing implants now offer a more effective solution.

    How the Growing Implant Works

    The growing implant, also called an expandable prosthesis, is placed after the tumor is removed. Unlike standard implants, it can lengthen gradually as the child grows. Many modern implants use magnetic technology, allowing doctors to extend the device during routine hospital visits without additional surgery.

    The gradual lengthening helps muscles, joints, and tissues adjust naturally, reducing pain and complications compared with older surgical methods.

    Benefits for Patients

    The implant offers several advantages:

    • Preserves the limb and improves mobility

    • Reduces the need for repeated surgeries

    • Maintains balanced limb growth

    • Supports long-term function and quality of life

    Lengthening procedures usually take only 15–20 minutes, allowing children to return to normal activities quickly.

    Future Developments

    While implants can be costly and occasionally require revision surgeries, advances in 3D printing, imaging, and customized surgical planning are improving their precision and durability.

    Growing implants are helping doctors focus on both curing cancer and ensuring children can lead active, independent lives after treatment. This innovation provides families facing bone cancer with renewed hope for survival and a better quality of life.

  • Researchers break decades-old bottleneck in chemotherapy drug manufacturing

     Researchers break decades-old bottleneck in chemotherapy drug manufacturing 

    An international team of researchers has achieved a breakthrough in the production of doxorubicin, a vital chemotherapy agent. The study identifies and resolves molecular “bottlenecks” that have limited the natural production of this drug for over 50 years. 
     
    Doxorubicin is a chemotherapy drug that was first approved for medical use in the 1970s. It is a cornerstone in treating various cancers, including breast cancer, bladder cancer, lymphomas and carcinomas, with over one million patients receiving the treatment annually. However, bacteria naturally produce this important drug very inefficiently. Consequently, the pharmaceutical industry has relied on expensive, multi-step semi-synthetic processes.

    Researchers break decades-old bottleneck in chemotherapy drug manufacturing

     

    “We have uncovered several independent factors that limit the formation of doxorubicin,” says Researcher, Keith Yamada, PhD, from the University of Turku in Finland, a lead scientist on the study. “By addressing these bottlenecks, we have harnessed rational strain engineering to pave the way for cost-effective manufacturing that can meet growing global demand”.

    Researchers develop new strain of bacteria that enhances drug production
    The study was the result of an extensive international collaboration involving a total of six research laboratories: the University of Turku in Finland, three laboratories in the United States, and two in Leiden, the Netherlands.

    Together, the teams identified three primary constraints that prevent the high-yield production of doxorubicin.

    Firstly, the team identified the specific natural “biological power supply” — redox partners named Fdx4 and FdR3 — that provide the necessary electron flow to power the drug-producing enzyme.

    Secondly, they discovered that a protein called DnrV acts as a drug-binding “molecular sponge”. It sequesters (binds and holds) doxorubicin so the drug does not shut down the enzyme’s own production machinery.

    Last, using X-ray crystallography, the team visualized the enzyme for the first time, revealing that the drug molecule sits in an unfavorable position within the enzyme, explaining the slow reaction rate.

    By combining these discoveries, the researchers engineered a new strain of bacteria that produces 180% more doxorubicin than current industrial standards.

    To bring these findings to the real world, the spin-out company Meta-Cells Oy was formed last year at the University of Turku. The company aims to commercialize these advanced technologies for the sustainable manufacturing of essential antibiotics and anti-cancer agents. This shift toward fully biosynthetic production promises a cleaner, more reliable supply of life-saving medicines.

    The study was published in the renowned journal Nature Communications.

    > Read the research article

  • Pulse of Positivity Hosts Health & Wellness Summit 2026 on March 15

    New Delhi, Mar 13: Pulse of Positivity will organise the Health & Wellness Summit on March 15, 2026, in New Delhi, bringing together policymakers, healthcare experts, academicians, and thought leaders to deliberate on key issues shaping India’s public health and wellness ecosystem. The summit will be held at Le Méridien, New Delhi, and will serve as a platform for dialogue on preventive healthcare, mental health awareness, lifestyle diseases, and sustainable health systems.

    Pulse of Positivity Hosts Health & Wellness Summit 2026 on March 15

     The inaugural session will feature Gajendra Singh Shekhawat, Union Minister for Culture and Tourism, Government of India, as the Chief Guest. The session will also include addresses from distinguished public leaders and the official launch of the “Health Chaupal” initiative, aimed at promoting community-driven dialogue on health and well-being.

    The event will also be graced by prominent dignitaries including Pankaj Kumar Singh, Minister for Health & Family Welfare, Government of NCT of Delhi, Temjen Imna Along, Minister for Higher Education & Tourism, Government of Nagaland, Anil Jain, President of The Bharat Scouts and Guides and former Member of Parliament (Rajya Sabha), and Raja Iqbal Singh, Mayor of Delhi.

    Designed as a multi-stakeholder platform, the summit will feature a series of thematic sessions bringing together medical practitioners, policy experts, and community leaders to discuss critical health challenges and opportunities.

    “The Health & Wellness Summit 2026 is envisioned as a platform to bring together policymakers, medical professionals, wellness practitioners and thought leaders to engage in meaningful dialogue on the future of healthcare in India. Through this summit, Pulse of Positivity aims to encourage conversations around preventive healthcare, mental well-being and community-driven health initiatives. We believe that collaborative dialogue and shared knowledge are essential to building a healthier, more aware and resilient society.” said Rear Admiral Kapil Gupta, VSM (Retd.), Editor-in-Chief of Pulse of Positivity.

    The summit will feature thematic sessions on mental health and emotional well-being, lifestyle diseases and preventive healthcare, women’s health and maternal–child wellness, and public health policy and sustainable health systems, bringing together experts from medicine, academia, wellness and public policy. Speakers include Gautam Chaubey, M. N. Hoda, Saroj Dubey, Raqib Ali, Vivek Kumar, Acharya Pratistha, Ambika Dhiman, Rajdeep Singh Anand, Shailendra Vyas, Bhawna Garg, Praveen Kumar Garg, Rahul Kashyap, RJ Ragini, Ravi Parashar, Navneet Bali, Arun Kumar Pandey, Rajeev Pathak, and Rajnikant Pandey, who will share perspectives on strengthening India’s healthcare ecosystem and promoting preventive and community-driven health practices.

    The summit will conclude with a Valedictory Session, featuring Tushar Chauhan, who secured All India Rank 216 in the Civil Services Examination 2025, alongside other distinguished speakers.

    Through discussions spanning mental health, preventive care, women’s health, and public policy, the Health & Wellness Summit aims to encourage knowledge exchange and foster collaborative solutions to strengthen India’s healthcare ecosystem while promoting community-driven wellness initiatives.

  • Lurie Autism Institute Announces Dr. Huda Zoghbi as the Inaugural Recipient of the Nancy Lurie Marks Prize for Autism Research

    Mar 13 – The Lurie Autism Institute, a joint initiative of Children’s Hospital of Philadelphia (CHOP) and Penn Medicine created to drive discovery, develop new treatments, and improve the lives of individuals and families affected by autism, is proud to announce that geneticist Huda Y. Zoghbi, MD, has been selected as the inaugural recipient of the Nancy Lurie Marks Prize for Autism Research, the Institute’s highest honor recognizing transformative contributions to autism research.

     Zoghbi is a Distinguished Service Professor in the Departments of Molecular and Human Genetics, Pediatrics, Neuroscience, and Neurology at Baylor College of Medicine, and Director of Texas Children’s Duncan Neurological Research Institute (Duncan NRI). She is also an Investigator at the Howard Hughes Medical Institute. A pioneering pediatric neurologist and physician–scientist, Zoghbi has fundamentally reshaped understanding of the genetic and molecular basis of neurological disease – including autism spectrum disorder – by integrating human genetics, animal models, and systems-level neuroscience to define how disruptions in gene regulation, neuronal maturation, and circuit function drive disease.

     “When thinking of an appropriate inaugural recipient of the Nancy Lurie Marks Prize for Autism Research, we wanted to consider the pre-eminent minds whose long history of incredible work in autism research continues to have a lasting effect,” said prize committee chair Frances E. Jensen, MD, Chair of the Department of Neurology and Professor of Neurology at the Perelman School of Medicine at the University of Pennsylvania and co-director of the Penn Translational Neuroscience Center. “Dr. Zoghbi’s record speaks for itself, and we couldn’t think of a more deserving inaugural recipient who exemplifies the pioneering work in autism research that the Lurie Autism Institute wants to make possible.”

     The Prize Selection Committee recognized Zoghbi for her landmark discovery that mutations in the MECP2 gene cause Rett syndrome, an autism-related neurodevelopmental disorder. This breakthrough transformed Rett syndrome from an enigmatic clinical condition into a foundational model for understanding autism genetics and neurobiology. Her work established core principles that have guided modern autism research; these principles now underpin contemporary large-scale genomic studies of autism and have shaped how investigators conceptualize risk, penetrance, and phenotypic variability across neurodevelopmental disorders.

     “I am deeply honored to receive the inaugural Nancy Lurie Marks Prize for Autism Research,” said Zoghbi. “Nancy’s dedication to autism research and to the families she so passionately championed has left an indelible mark on our field. The Lurie Autism Institute’s continued commitment to advancing impactful autism research benefits us all.  I share this recognition with the patients and families who inspire our work every day, and with the remarkable trainees and collaborators whose insight, creativity, and dedication have advanced our understanding of how genetic disruptions alter brain function.” She continued, “I hope that continued progress in this field will lead to better insights and treatments, ultimately improving the lives of individuals with autism and their families. This honor serves as a powerful reminder of the promise rigorous science holds for truly transforming lives.”

     By demonstrating that de novo mutations underlie Rett syndrome, Dr. Zoghbi helped catalyze study designs that enrich for de novo variation. These studies served as an important basis for projects such as the Simons Simplex Collection, a core project and resource of the Simons Foundation Autism Research Initiative (SFARI) that establishes a permanent repository of genetic samples of families of children with autism. This framework was then later adopted by the Simons Foundation Powering Autism Research for Knowledge (SPARK) and the Autism Sequencing Consortium. This paradigm led to the discovery of dozens of de novo variants and hundreds of autism-related genes, many of which encode chromatin regulators, firmly establishing epigenetic and chromatin-mediated mechanisms as central pathways in autism.

     “Dr. Zoghbi’s incredible discoveries of some key biological mechanisms underlying autism are important steps in the journey we’re on with the Lurie Autism Institute to provide patients with more answers,” said Daniel Rader, MD, Interim Director, Lurie Autism Institute and Chief of Translational Medicine and Human Genetics, Penn Medicine and CHOP. “Her central role in advancing our understanding of neurobiology and translating that basic science into clinical progress makes her an extremely deserving recipient of the inaugural Nancy Lurie Marks Prize for Autism Research.”

     The Nancy Lurie Marks Prize for Autism Research honors the legacy of Nancy Lurie Marks, whose visionary philanthropy has played a pivotal role in advancing autism research and improving the lives of individuals with autism. The Prize includes a $100,000 award and recognizes a single individual whose work has made a profound and lasting impact on the field.

     “The Lurie Autism Institute was established to usher in a new era of scientific discovery in autism, and the work of extraordinary talents like Dr. Zoghbi exemplifies the kind of breakthrough discoveries we hope to make possible,” said Jeffrey Lurie, Chairman and CEO of the Philadelphia Eagles and founder of the Eagles Autism Foundation.

     Zoghbi will be formally honored at the 2026 Lurie Autism Institute Symposium, to be held on May 7, 2026, in Philadelphia, where she will deliver a featured lecture.

     The Lurie Autism Institute, which reflects the combined strength of Children’s Hospital of Philadelphia and Penn Medicine, was made possible through the generosity of the Lurie Family Foundation and the Nancy Lurie Marks Family Foundation. Launched in June, 2025, the Institute is dedicated to advancing autism science and care, while aiming to accelerate discovery, deepen understanding of autism’s complexities and improve outcomes for individuals and families.

  • kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics

    Paris, 9 March, 2026 – kyron.bio, a biotechnology company pioneering precision glycoengineering for antibody therapeutic development, today announced a strategic partnership with Servier, an international pharmaceutical group governed by a Foundation.

    Under the terms of the agreement, kyron.bio will use its technology to glycoengineer an antibody selected by Servier, who will fund the associated research activities. Servier will have the option to further explore antibody engineering and development opportunities based on the outcomes. Financial details are not disclosed.

    kyron.bio’s proprietary glycoengineering platform can enhance therapeutic performance of antibodies by enabling precise control of the glycan structures to improve efficacy, safety, and scalability. In this partnership kyron.bio will seek to demonstrate clear glycan control on the Servier antibody of interest for a specific pre-determined N-glycoform.

    To date, engineering of glycans have been under-exploited, due to technical challenges, limiting the use of glycan engineering in drug design. kyron.bio is changing that. The company has developed a scalable, proprietary method to achieve comprehensive control over glycosylation, unlocking the possibility to use precision glycosylation in next generation drug design.

    Dr. Emilia McLaughlin, founder and Chief Executive Officer of kyron.bio said,

    “We are delighted that Servier has chosen to explore the potential of our glycoengineering platform. Servier has deep expertise in therapeutic development and combined with our precision glycosylation technology, this partnership provides a powerful opportunity to unlock new levels of antibody performance and deliver better outcomes for patients.

    “Precision glycosylation represents a transformative approach in biologics development. By engineering defined glycan profiles, therapeutic antibodies can be optimized for improved immune engagement, pharmacokinetics, and reduced variability.”

    In 2024, kyron.bio was the winner of the Servier Golden Ticket award which has provided invaluable support and mentorship through the company’s early translational phase and has developed a foundation for understanding the potential of kyron.bio’s technology.

    Dr. Emmanuel Nony, Director of External Innovation Europe at Servier said,

    “Meeting kyron.bio as a winner of Servier’s Golden Ticket award has enabled our scientists to develop an understanding of the kyron.bio glycan engineering technology and its exciting possibilities in antibody drug design. This collaboration is opening new frontiers for antibody derivatives as well. Together, we are exploring innovative pathways to optimize drug design and production, with a shared commitment to bringing safer and more effective therapies to patients.”

    kyron.bio’s strategy is to form strategic drug design partnerships with pharmaceutical and biotech companies working on next-generation antibody therapeutics, alongside in house therapeutic development programs.

    A successful company creation from the French Entrepreneur First Scheme, in 2025 kyron.bio raised €5.5m in a seed round from an experienced syndicate of venture investors including HCVC, Verve Ventures, Entrepreneurs First and Saras Capital, as well as private angel investors and the European Innovation Council. It has established an R&D base at the biotech hub Paris Biotech Santé in the Cochin Hospital.

  • kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics

    Innovative glycobiology platform aimed at enhancing the efficacy, safety, and scalability of next-generation antibody therapeutics across multiple disease areas

    Paris, Mar 09 – kyron.bio, a biotechnology company pioneering precision glycoengineering for antibody therapeutic development, today announced a strategic partnership with Servier, an international pharmaceutical group governed by a Foundation.

    Under the terms of the agreement, kyron.bio will use its technology to glycoengineer an antibody selected by Servier, who will fund the associated research activities. Servier will have the option to further explore antibody engineering and development opportunities based on the outcomes. Financial details are not disclosed.

    kyron.bio’s proprietary glycoengineering platform can enhance therapeutic performance of antibodies by enabling precise control of the glycan structures to improve efficacy, safety, and scalability. In this partnership kyron.bio will seek to demonstrate clear glycan control on the Servier antibody of interest for a specific pre-determined N-glycoform.

    To date, engineering of glycans have been under-exploited, due to technical challenges, limiting the use of glycan engineering in drug design. kyron.bio is changing that. The company has developed a scalable, proprietary method to achieve comprehensive control over glycosylation, unlocking the possibility to use precision glycosylation in next generation drug design.

    Dr. Emilia McLaughlin, founder and Chief Executive Officer of kyron.bio said,

    “We are delighted that Servier has chosen to explore the potential of our glycoengineering platform. Servier has deep expertise in therapeutic development and combined with our precision glycosylation technology, this partnership provides a powerful opportunity to unlock new levels of antibody performance and deliver better outcomes for patients.

    “Precision glycosylation represents a transformative approach in biologics development. By engineering defined glycan profiles, therapeutic antibodies can be optimized for improved immune engagement, pharmacokinetics, and reduced variability.”

    In 2024, kyron.bio was the winner of the Servier Golden Ticket award which has provided invaluable support and mentorship through the company’s early translational phase and has developed a foundation for understanding the potential of kyron.bio’s technology.

    Dr. Emmanuel Nony, Director of External Innovation Europe at Servier said,

    “Meeting kyron.bio as a winner of Servier’s Golden Ticket award has enabled our scientists to develop an understanding of the kyron.bio glycan engineering technology and its exciting possibilities in antibody drug design. This collaboration is opening new frontiers for antibody derivatives as well. Together, we are exploring innovative pathways to optimize drug design and production, with a shared commitment to bringing safer and more effective therapies to patients.”

    kyron.bio’s strategy is to form strategic drug design partnerships with pharmaceutical and biotech companies working on next-generation antibody therapeutics, alongside in house therapeutic development programs.

    A successful company creation from the French Entrepreneur First Scheme, in 2025 kyron.bio raised €5.5m in a seed round from an experienced syndicate of venture investors including HCVC, Verve Ventures, Entrepreneurs First and Saras Capital, as well as private angel investors and the European Innovation Council. It has established an R&D base at the biotech hub Paris Biotech Santé in the Cochin Hospital.

  • Bharati Jajoo Reframes Women’s Health Across Every Decade

    Bengaluru, Mar 9: Happiest Health successfully hosted the third edition of its Women’s Wellness Summit, ‘Happiest Her 2026’, at the NIMHANS Auditorium. Held on International Women’s Day, the half-day summit brought together healthcare experts, wellness practitioners, and women professionals to engage in meaningful conversations around holistic wellbeing, focusing on mind, movement, and preventive care.

    Bharati Jajoo Reframes Women’s Health Across Every Decade

     The summit served as a dedicated platform encouraging women to prioritise their physical and emotional health while balancing demanding professional and personal responsibilities. Through expert-led discussions and experiential sessions, the event highlighted the importance of proactive and preventive healthcare practices.

    The event was inaugurated by Tina Mitra, Chief Revenue Officer, Happiest Health, along with Bharati Jajoo, India’s leading ergonomics expert and Clinical Director of Body Dynamics at Happiest Health, along with other distinguished guests.

    Delivering the keynote address, Bharati Jajoo encouraged women to reflect on a powerful question: “What would my 60-year-old self thank me for today?” She emphasised that women often spend decades caring for family, work, and responsibilities while neglecting their own wellbeing.

    “True well-being begins when we reclaim that space for ourselves. By paying attention to the four pillars—sleep, movement, nutrition, and relaxation—we can build resilience that supports us through every stage of life. Small, consistent choices today can shape a stronger, healthier future for women in the decades ahead,” she said.

    Her session also highlighted the growing impact of sedentary lifestyles, poor posture, and workplace strain on women’s long-term health. She emphasised the importance of ergonomic awareness, conscious movement, and preventive interventions as sustainable approaches to wellbeing.

    Sharing his perspective, Raghu Krishnan, Co-CEO Knowledge and Chief Editor and Publisher (Print) at Happiest Health, said:

    “Prioritising one’s health—exercise, nutrition, sleep, and mental wellness is essential. Participants at Happiest Her gained valuable insights from leading experts on managing health and wellbeing in the midst of our busy lives.”

    An engaging panel discussion titled “Women & Me-Time” explored how women balancing multiple roles can achieve holistic fitness through informed lifestyle choices, early preventive care, and structured wellness habits.

    One of the key highlights of the summit was an experiential session on Dance Movement Therapy conducted by Preeti Rajagopalan, a practitioner associated with the Creative Movement Therapy Association of India. The immersive session encouraged participants to reconnect with their bodies through expressive movement, reinforcing the strong connection between emotional expression and physical wellbeing.

    The event also featured curated engagement activities, interactive games, and a networking lunch, allowing participants to exchange perspectives and build supportive wellness communities. Staying true to its theme “Pause. Connect. Recharge.” the summit created an energising space for women to reflect on and invest in their wellbeing.

    Adding a practical dimension to the event was a Physical Health Screening Booth hosted by Happiest Body Dynamics and Happiest Physio Clinic, where participants were encouraged to proactively assess key aspects of their physical health. Nearly 70 percent of attendees participated in the screening, which evaluated parameters such as posture, balance, pelvic strength, flexibility, and bone health.

    Each participant received individual scores across these metrics, along with a comprehensive assessment and personalised clinical recommendations from qualified physiotherapists, reinforcing the summit’s emphasis on preventive and informed healthcare.

    Now in its third edition, Happiest Her continues to strengthen its position as a trusted and knowledge-driven initiative, reflecting Happiest Health’s commitment to delivering expert-backed health information and empowering women to make informed decisions about their wellbeing.